Date: Jan 30, 2013 Source: (
click here to go to the source)
Rockville, MD,
January 30, 2013 --
The terminated, June, 2010 License Agreement
provided
Bioniche
commercial access to Trophogen's internationally
patented, superagonist
hormone technology platform, which was developed by Trophogen and originally licensed
from the National Institutes of Health for the veterinary field.
Termination is not linked to the performance of Trophogen's novel, recombinant, single-
injection superagonist bovine FSH analog, for which Bioniche presented encouraging
preliminary clinical data in cows at the International Congress on Animal Reproduction in
Vancouver, B.C. on July 31, 2012.
Bioniche and Trophogen published a press release
regarding the presentation that same day
(PRN PRESS RELEASE on July 31, 2012)
.
